CYCC Share Price

Open 1.72 Change Price %
High 1.91 1 Day 0.20 11.70
Low 1.72 1 Week -1.18 -38.19
Close 1.91 1 Month -2.21 -53.64
Volume 2640990 1 Year -2.89 -60.21
52 Week High 10.90
52 Week Low 1.71
CYCC Important Levels
Resistance 2 2.09
Resistance 1 2.01
Pivot 1.85
Support 1 1.81
Support 2 1.73
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ASTI 0.00 0.00%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

CYCC Technical Analysis 5
As on 21st Jul 2017 CYCC Share Price closed @ 1.91 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.74 & Strong Sell for SHORT-TERM with Stoploss of 4.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYCC Target for July
1st Target up-side 4.2
2nd Target up-side 4.5
3rd Target up-side 4.8
1st Target down-side 3.34
2nd Target down-side 3.04
3rd Target down-side 2.74
CYCC Other Details
Segment EQ
Market Capital 58250856.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cyclacel.com
CYCC Address
CYCC
200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
United States
Phone: 908-517-7330
Fax: 866-271-3466
CYCC Latest News
Interactive Technical Analysis Chart Cyclacel Pharmaceuticals, Inc. ( CYCC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cyclacel Pharmaceuticals, Inc.
CYCC Business Profile
Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology, oncology, and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer, multiple myeloma and chronic lymphocytic leukemia.